Other Pharmaceuticals - Portugal

Portugal

Revenue in Portugal's Other Pharmaceuticals market is projected to reach US$0.97bn in 2024.
The market is expected to show an annual growth rate (CAGR 2024-2029) of 0037, resulting in a market volume of US$1.19bn by 2029.
In global comparison, United States is set to generate the highest revenue, reaching US$260.50bn in 2024.
Portugal's pharmaceutical market is experiencing a rise in demand for alternative medicines and natural remedies.

Key regions: China, Europe, Australia, United States, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Pharmaceuticals market in Portugal has seen significant growth in recent years.

Customer preferences: Customers in Portugal have shown a growing interest in alternative medicines and natural remedies, leading to an increased demand for Other Pharmaceuticals. This trend is in line with the global shift towards more natural and holistic approaches to healthcare.

Trends in the market: The Other Pharmaceuticals market in Portugal has been growing steadily due to the increasing demand for alternative medicines. Additionally, the aging population in Portugal has led to a rise in chronic diseases, which has further boosted the demand for Other Pharmaceuticals.

Local special circumstances: Portugal has a well-established healthcare system, which has helped to support the growth of the Other Pharmaceuticals market. The country also has a strong tradition of using natural remedies, which has made it easier for alternative medicines to gain acceptance among the population.

Underlying macroeconomic factors: The Portuguese economy has been recovering from the financial crisis of the late 2000s, which has led to an increase in disposable income and a greater willingness to spend on healthcare. Additionally, the government has been investing in healthcare infrastructure, which has helped to support the growth of the Other Pharmaceuticals market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.